Intravitreal Aflibercept 8 mg in Patients With Polypoidal Choroidal Vasculopathy (PCV): A 96-week Phase 3 PULSAR Trial Subgroup Analysis

Chui Ming Gemmy Cheung,[1,2] Tien Yin Wong,[1,3] Jeffrey S Heier,[4] Xin Zhang,[5] Tobias Machewitz,[6] Andrea Schulze,[6] Sergio Leal,[5] on behalf of the PULSAR study investigators

[1]Singapore Eye Research Institute, Singapore National Eye Centre, Singapore
[2]Duke-NUS Medical School, National University of Singapore, Singapore
[3]Tsinghua Medicine, Tsinghua University, Beijing, China
[4]Ophthalmic Consultants of Boston, Boston, MA, USA
[5]Bayer Consumer Care AG, Basel, Switzerland
[6]Bayer AG, Berlin, Germany

Presented at the 47th Annual Macular Society Meeting, Palm Springs, CA, USA, February 7–10, 2024

Disclosures

pulsar
nAMD

- **CMGC:** Consultant fees, speaker fees, and grant funding from Avirmax, Bayer, Boehringer Ingelheim, Janssen, Novartis, Roche, Topcon, and Zeiss
  - **TYW:** Consultant fees from Bayer, Boehringer-Ingelheim, Eden Ophthalmic, Genentech, Iveric Bio, Novartis, Roche, Shanghai Henlius, and Zhaoke Pharmaceutical. **JSH:** Consultant fees from 4DMT, Abpro, Adverum, Affamed, AGTC, Akouos, Allegro, Annexon, Apellis, Asclepix, Bausch & Lomb, Biovisics, Clearside, Curacle, DTx Pharma, Genentech/Roche, Glaukos, Gyroscope, Immunogen, Iveric, Janssen R&D, jCyte, Kriya, Nanoscope, NGM, Notal Vision, Novartis, Ocular Therapeutix, Ocuphire, OcuTerrra, Olix, ONL Therapeutics, Palatin, Perceive, Ray Therapeutics, Regeneron, Regenxbio, RetinAI, RevOpsis, Stealth, Thea, and Vanotech; research funding from Annexon, Apellis, AsclepiX, Bayer, Genentech/Roche, Gyroscope, Iveric, Kodiak, NGM, Notal Vision, Regeneron, and Regenxbio; equity in Adverum, Aldeyra, Allegro, Aviceda, DTx Pharma, jCyte, Ocuphire, Ocular Therapeutix, RevOpsis, Vinci, and Vitranu; and member of the Board of Directors of Ocular Therapeutix. **XZ and SL:** Employees of Bayer Consumer Care AG. **TM and AS:** Employees of Bayer AG
- The PULSAR study (NCT04423718) was sponsored by Bayer AG (Leverkusen, Germany) and co-funded by Regeneron Pharmaceuticals, Inc. (Tarrytown, NY, USA). The sponsor participated in the design and conduct of the study, analysis of the data, and preparation of this presentation
- Study disclosures: This study includes research conducted on human patients. Institutional Review Board approval was obtained prior to study initiation
- The data in this presentation were originally presented at the 16th Asia-Pacific Vitreo-Retina Society (APVRS) Congress, Hong Kong, China, December 8–10, 2023
- Medical writing support, under the direction of the authors, was provided by ApotheCom and funded by Bayer Consumer Care AG (Basel, Switzerland), in accordance with Good Publication Practice (GPP) guidance (*Ann Intern Med* 2022;175:1298–1304)

PULSAR: Multicenter, randomized, double-masked study

pulsar nAMD

Patients with treatment-naïve nAMD, randomized at baseline

2q8	8q12	8q16
Aflibercept 2 mg every 8 weeks after 3 initial monthly injections n=336	Aflibercept 8 mg every 12 weeks after 3 initial monthly injections n=335	Aflibercept 8 mg every 16 weeks after 3 initial monthly injections n=338

	YEAR 1													YEAR 2										
	Day 1	W4	W8	W12	W16	W20	W24	W28	W32	W36	W40	W44	W48	W52	W56	W60	W64	W68	W72	W76	W80	W84	W88	W92	W96
2q8	X	X	X		X	o	X	o	X	o	X	o	X	o	X	o	X	o	X	o	X	o	X	o	–
8q12	X	X	X		o[a]	X[a]	o	o	X[a]	o	o	X[a]	o	o	X[a,b]	o	o	X[a,b]	o	o	X[a,b]	o	o	X[a,b]	–
8q16	X	X	X		o[a]	o[a]	X[a]	o	o	o	X[a]	o	o	o	X[a,b]	o	o	o	X[a,b]	o	o	o	X[a,b]	o	–

Primary endpoint at W48:
Mean change in BCVA (non-inferiority)

End of study at W96 with optional ~1-year extension through W156

[a]DRM: Interval Shortening During Years 1 and 2

Criteria for interval shortening
- >5-letter loss in BCVA compared with Week 12 due to persistent or worsening nAMD **AND**
- >25 µm increase in CRT compared with Week 12, **OR** new foveal neovascularization, **OR** new foveal hemorrhage

- Patients who met DRM criteria had dosing intervals shortened to q8 at **Weeks 16** and **20** or by 4-week increments from **Week 24**
  - The minimum assigned dosing interval was q8

[b]DRM: Interval Extension During Year 2

Criteria for interval extension
- <5-letter loss in BCVA compared with Week 12 **AND**
- No fluid at the central subfield on OCT **AND**
- No new foveal hemorrhage or foveal neovascularization

- Patients who met DRM criteria from **Weeks 52 through 96** had dosing intervals extended by 4-week increments
  - The maximum assigned dosing interval was q24

Figure does not reflect all dosing options once a patient's dosing interval is shortened or extended. Stippled boxes = initial treatment phase; X = active injection; o = sham injections.
q8, every 8 weeks; **q24**, every 24 weeks; **BCVA,** best-corrected visual acuity; **CRT**, central retinal thickness; **DRM**, dose regimen modification; **nAMD**, neovascular age-related macular degeneration; **OCT**, optical coherence tomography; **W**, week.

PULSAR: ICGA-Confirmed PCV in 139 Patients

pulsar nAMD

- PULSAR is a global study conducted across 223 sites in 27 countries
- **ICGA was optional and conducted in 296 patients in 13 countries**[a]
  - **PCV present, n=139; PCV absent, n=154**
  - PCV could not be graded in 3 patients

PCV Subgroup by Race[b]



BL demographics and disease characteristics	PCV Subgroup (ICGA-confirmed)				Overall Population			
	2q8	8q12	8q16	All 8 mg	2q8	8q12	8q16	All 8 mg
	n=54	n=44	n=41	n=85	n=336	n=335	n=338	n=673
Age, years	72.6 (8.2)	72.2 (8.1)	73.2 (8.7)	72.7 (8.3)	74.2 (8.8)	74.7 (7.9)	74.5 (8.5)	74.6 (8.2)
Female, %	31.5	50.0	36.6	43.5	56.0	54.3	53.3	53.8
BCVA, ETDRS letters	57.6 (15.5)	56.3 (13.3)	60.1 (11.5)	58.1 (12.5)	58.9 (14.0)	59.9 (13.4)	60.0 (12.4)	59.9 (12.9)
CST, μm	378 (163)	392 (129)	377 (139)	384 (134)	367 (134)	370 (124)	371 (133)	371 (128)
CNV size, mm^2	5.8 (4.7)	5.1 (3.8)	5.2 (4.5)	5.1 (4.2)	6.4 (5.0)	6.0 (4.8)	6.5 (5.5)	6.3 (5.2)

FAS, data are mean (SD) unless otherwise indicated. ICGA images were graded by the reading center. [a]Australia (n=15); Austria (n=7); Estonia (n=1); France (n=2); Italy (n=22); Japan (n=70); Latvia (n=2); Mainland China (n=65); Singapore (n=1); South Korea (n=25); Spain (n=3); Switzerland (n=3); USA (n=77). [b]No patients were reported as being Black or African American, or multi-racial.
BL, baseline; **CNV**, choroidal neovascularization; **CST**, central subfield thickness; **ETDRS,** Early Treatment Diabetic Retinopathy Study; **FAS**, full analysis set; **ICGA,** indocyanine green angiography.

Change in BCVA Through Week 96: Similar With 8q12 and 8q16 Versus 2q8

pulsar nAMD

PCV Subgroup



	BL	Week 48	Week 96
2q8 (n=54)	57.6	+9.3	+9.6
8q12 (n=44)	56.3	+9.5	+8.4
8q16 (n=41)	60.1	+7.5	+8.2

Overall Population



	BL	Week 48	Week 96
2q8 (n=336)	58.9	+7.5	+7.1
8q12 (n=335)	59.9	+6.1	+5.5
8q16 (n=338)	60.0	+5.9	+5.4

PCV Subgroup	Mean ± SD change from BL to Week 96 (LOCF)	Two-sided 95% CI	Overall Population	Mean ± SD change from BL to Week 96 (LOCF)	Two-sided 95% CI
2q8	+9.6 ± 12.1	6.3, 12.9	2q8	+7.1 ± 13.0	5.7, 8.5
8q12	+8.4 ± 12.8	4.5, 12.3	8q12	+5.5 ± 14.9	3.9, 7.1
8q16	+8.2 ± 9.0	5.4, 11.1	8q16	+5.4 ± 13.3	4.0, 6.8

FAS, LOCF (last available observed value prior to ICE was used to impute missing data; ICE were handled according to sensitivity estimand strategy for continuous endpoints, as described).
N values are number of patients with BCVA assessments at baseline.
ICE, intercurrent event; **LOCF,** last observation carried forward.

CST Through Week 96: Similar with 8q12 and 8q16 Versus 2q8

pulsar nAMD

PCV Subgroup



	Week 48	Week 96
2q8 (n=54)	216	207
8q12 (n=44)	219	219
8q16 (n=41)	230	232

Overall Population



	Week 48	Week 96
2q8 (n=335)	236	225
8q12 (n=333)	228	223
8q16 (n=334)	227	225

PCV Subgroup	Mean ± SD change from BL to Week 96 (LOCF)	Two-sided 95% CI	Overall Population	Mean ± SD change from BL to Week 96 (LOCF)	Two-sided 95% CI
2q8	−157 ± 140	−195, −118	2q8	−141 ± 132	−155, −126
8q12	−172 ± 139	−215, −130	8q12	−147 ± 128	−161, −133
8q16	−145 ± 142	−190, −100	8q16	−145 ± 135	−160, −131

FAS, LOCF. N values are number of patients with CST assessments at baseline.

Retinal Fluid Through Week 96: Marked Increase in Proportion of Patients Without Retinal Fluid

pulsar nAMD

PCV Subgroup



FAS, LOCF (data post ICE were censored). "Without retinal fluid" defined as absence of intraretinal and subretinal fluid in central subfield.

Dosing Interval Extension in Year 2[a]: Most Patients with PCV Qualified for Extension

nAMD

Last Assigned Dosing Interval (PCV Subgroup)



PCV Subgroup[b]	Mean number of injections from baseline to Week 96
2q8	12.7
8q12	9.7
8q16	7.7

[a]Dosing intervals were extended in Year 2 if patients had <5-letter loss in BCVA from Week 12 **AND** no fluid at the central subfield **AND** no new foveal hemorrhage or neovascularization.
[b]Patients completing Week 96. [c]Patients were assigned to 24-week dosing intervals if they continued to meet extension criteria; study duration did not allow enough time for patients to complete the interval within the 96-week study period. Values may not add up to 100% due to rounding.
q12, every 12 weeks; **q16**, every 16 weeks; **q20**, every 20 weeks.

Polypoidal Lesions Through Week 48

pulsar nAMD

~50% of patients had no polypoidal lesions at Week 48[a]



≥78% of patients had no active polypoidal lesions[a,d] at Week 48



Data are for patients with PCV who completed week 48. Screening (visit 1) occurred before the baseline visit (visit 2). [a]For polypoidal lesion data: 2q8, n=51; all 8 mg, n=78 (% calculated based on number of patients with known number of polypoidal lesions). [b]At week 48, number of polypoidal lesions unknown for n=6 and n=9 in 2q8 and all 8 mg groups, respectively. [c]Patients shown here with no polypoidal lesions at screening were those who were first tested by ICGA at baseline. [d]"No" active polypoidal lesions defined as no polypoidal lesions present **OR** IRF and SRF are "absent" or "questionable". [e]At week 48, n=2 unknown each for 2q8 and all 8 mg groups. **IRF**, intraretinal fluid; **SRF**, subretinal fluid.

Total Area of Polypoidal Lesions: Similar Change From Baseline Through Week 96

pulsar nAMD

PCV Subgroup



Data are for patients with PCV who completed Week 96.

96-Week Ocular Safety Profile of Aflibercept 8 mg: Similar to 2 mg in PCV and Overall Populations

pulsar nAMD

TEAE, n (%) in study eye	PCV subgroup				Overall population			
	2q8	8q12	8q16	All 8 mg	2q8	8q12	8q16	All 8 mg
	n=54	n=44	n=41	n=85	n=336	n=335	n=338	n=673
Any ocular TEAE	21 (38.9)	20 (45.5)	20 (48.8)	40 (47.1)	181 (53.9)	171 (51.0)	174 (51.5)	345 (51.3)
Any intraocular inflammation TEAE	1 (1.9)	1 (2.3)	0	1 (1.2)	7 (2.1)	6 (1.8)	3 (0.9)	9 (1.3)

- Ocular TEAEs occurring in ≥5% of patients in any treatment arm in the PCV subgroup were retinal hemorrhage, conjunctival hemorrhage, reduced visual acuity, vitreous floaters, conjunctivitis, intraocular pressure increased, (worsening of) AMD, dry eye, and macular edema
- Two cases of intraocular inflammation occurred in the PCV subgroup: chorioretinitis (reported term: posterior uveitis)[a] and eye inflammation; both cases were mild in intensity and neither case was considered serious

Data are from the SAF. TEAEs are AEs occurring from the first injection to 30 days after the last injection (active or sham); ocular TEAEs are those occurring in the study eye.
[a]The case of chorioretinitis was not considered to be related to the study drug.
AE, adverse event; **AMD**, age-related macular degeneration; **TEAE**, treatment-emergent adverse event; **SAF**, safety analysis set.

Conclusions: Aflibercept 8 mg Monotherapy in PCV

pulsar nAMD

Aflibercept 8 mg monotherapy[a] largely maintained efficacy in PCV over 2 years

- **Visual acuity gains** from baseline were **largely maintained from Week 48 to Week 96** in the aflibercept 8q12, 8q16, and 2q8 PCV subgroups, with gains of +8.4, +8.2, and +9.6 letters, respectively, from baseline to Week 96
- Through Week 96, the absolute and mean change in **CST** from baseline were numerically **similar** in the 3 treatment arms
- Both aflibercept 8 mg and 2 mg **markedly reduced the total polypoidal lesion area from baseline to Week 96**

Extended durability

- At Week 96, **72%** of patients with PCV treated with aflibercept 8q16 qualified for an **extended dosing interval of ≥20 weeks**, suggesting **extended durability of aflibercept 8 mg** versus aflibercept 2 mg

Comparable safety profile for aflibercept 8 mg versus 2 mg

- In the PULSAR study, the **safety profile of aflibercept 8** mg was **similar to that of aflibercept 2 mg** in the PCV subgroup and overall study population

[a]Without active rescue photodynamic therapy.